Table 1 lists the clinical features of patients in the present series. The mean (SD) age of the patients at first presentation was 26-3 (14-1) years for women (n = 70) and 21-1 (11-9) years for men (n = 75); 33 1% were under 15. Thirty one (21 %) patients had had symptoms for less than 2 years before presentation to the hospital. Seventy two (49.7%) were in New York Heart Association functional classes III and IV at first presentation. The proportion of patients with right and left heart failure was the same at first presentation (37 9%). Apart from atrial fibrillation, arrhythmias were uncommon in these patients. Ventricular extrasystoles were seen in five (3-40/%). Sixteen (11-03%) of the patients were anaemic (haemoglobin < 100 g/l). The large proportion of patients belonging to the New York Heart Association classes , with ascites (40 0%), peripheral oedema (24 8%), cardiothoracic ratio > 60% (57-2%), and other features show how 450 on 11 May 2018 by guest. Protected by copyright.

It is important to minimize trauma to the vessel, avoid repetitive balloon dilatations use direct stenting and use the shortest stent if possible.

Background and aims It is not known if new onset diabetes during Coronavirus-19 disease (COVID-19; NOD COVID) is phenotypically or biochemically different than new onset diabetes before COVID-19 (NOD). Methods All adults diagnosed with new onset diabetes from during the time of COVID-19 were compared with new onset diabetes prior to COVID-19, from two tertiary care hospitals in Chennai and Delhi. RTPCR test for SARS-CoV-2 virus was done as appropriate, and COVID-19 antibody test was done in all other NOD COVID patients. Result A total of 555 patients with new onset diabetes were included in the study (282 NOD and 273 NOD COVID patients). Patients with NOD COVID had higher fasting and post prandial blood glucose and glycated hemoglobin vs. NOD patients. Both the groups had high average body mass index; ∼28 kg/m2. Interestingly, fasting C-peptide levels were significantly higher in the NOD COVID group vs. NOD group. There was no difference in C-peptide or glycemic parameters between the COVID-19 antibody positive and negative NOD COVID cases. Conclusion Individuals who were diagnosed with diabetes during COVID-19 epidemic (NOD COVID) do not significantly differ from those diagnosed before COVID-19 in symptomatology, phenotype, and C-peptide levels but they had more severe glycemia.